Source: Eur Respir J 2004; 24: 466-470
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Liapakis I.E., Kottakis I., Tzatzarakis M.N., Tsatsakis A.M., Pitiakoudis M.S., Ypsilantis P., Light R.W., Simopoulos C.E., Bouros D.E.. Penetration of newer quinolones in the empyema fluid. Eur Respir J 2004; 24: 466-470

Member's Comments

No comment yet.

Related content which might interest you: Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002 Resistance of Streptococcus pneumoniae to penicillin, azitromycin, ciprofloxacyn and ceftriaxon Source: Eur Respir J 2001; 18: Suppl. 33, 140s Year: 2001 New antibiotics for VAP Source: Eur Respir Mon 2011; 53: 48-53 Year: 2011 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Comparison of immunomodulating effects among clarithromycin, dexamethasone and levofloxacin on the murine model of mycoplasma pneumoniae pneumonia Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Pharmacokinetics and pharmacoynamics of clarithromycin in the empyema pleural fluid Source: Eur Respir J 2004; 24: Suppl. 48, 637s Year: 2004 Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Therapeutic efficacy of macrolides, minocycline and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Penetration of azithromycin in experimental pleural empyema model fluid Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Aerosolised treatment for VAP Source: Eur Respir Mon 2011; 53: 54-65 Year: 2011 Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Penetration of linezolide in experimental pleural empyema model fluid Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007 Use of respiratory fluoroquinolones gatifloxacin for treatment of severe community-acquired pneumonia (SCAP) Source: Eur Respir J 2006; 28: Suppl. 50, 166s Year: 2006 Treatment challenges in methicillin resistant Staphylococcus aureus infections Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Tobramycin by aerosol (Toby®) eradicates Pseudomonas aeruginosa resistant to Tobramycin i.v. in patients with infected bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001 Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004